Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors... Show more
On July 01, 2025, the Stochastic Oscillator for LIXT moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 60 instances where the indicator left the oversold zone. In of the 60 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
The Momentum Indicator moved above the 0 level on July 01, 2025. You may want to consider a long position or call options on LIXT as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for LIXT just turned positive on July 01, 2025. Looking at past instances where LIXT's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
LIXT moved above its 50-day moving average on July 02, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LIXT crossed bullishly above the 50-day moving average on July 07, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +6 3-day Advance, the price is estimated to grow further. Considering data from situations where LIXT advanced for three days, in of 195 cases, the price rose further within the following month. The odds of a continued upward trend are .
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LIXT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
LIXT broke above its upper Bollinger Band on July 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LIXT entered a downward trend on June 24, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LIXT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.005) is normal, around the industry mean (17.368). P/E Ratio (0.000) is within average values for comparable stocks, (59.372). LIXT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.445). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (273.506).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIXT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Industry Biotechnology
A.I.dvisor indicates that over the last year, LIXT has been loosely correlated with PTHS. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if LIXT jumps, then PTHS could also see price increases.
Ticker / NAME | Correlation To LIXT | 1D Price Change % | ||
---|---|---|---|---|
LIXT | 100% | +53.45% | ||
PTHS - LIXT | 34% Loosely correlated | +60.78% | ||
SONN - LIXT | 34% Loosely correlated | +13.79% | ||
NTLA - LIXT | 28% Poorly correlated | +0.25% | ||
IBIO - LIXT | 28% Poorly correlated | -1.24% | ||
BBIO - LIXT | 27% Poorly correlated | +0.63% | ||
More |